Introduction
The benefit of using α-emitting radionuclides in cancer therapy is well established [1] . Their high linear energy transfer and short range in tissue give them advantages over β-and γ-emitting radionuclides in terms of more effective cancer cell inactivation and less damage to surrounding normal tissue when used in targeted therapy. The awareness of α-emitting radionuclides for cancer therapy has increased after the FDA approval of 223 Ra-dichloride, Xofigo®, as the first in class α-emitting radiopharmaceutical. Xofigo® is approved for treatment of patients with metastatic castration-resistant prostate cancer disseminated to the bones. In contrast to Xofigo®, where the resemblance of the 223 Ra-isotope to calcium naturally guides the radionuclide to the bones, the majority of proposed α-therapies require the use of a targeting molecule. Most widespread is the use of a protein, such as a monoclonal antibody or a peptide, as the targeting moiety.
Even if the potential of α-emitters in targeted cancer therapy is wellknown, very few α-emitting radionuclides are suitable for radiotherapeutic purposes. Many have shortcomings related to inconvenient half-lives (either too short or too long), lack of viable chemistry to link them to targeting molecules, difficulties in production and/or availability concerns [2] . One radionuclide which has been suggested and examined for applications in targeted α-therapy is 212 Pb. It is part of the 
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Nuclear Medicine and Biology j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / n u c m e d b i o potent α-emitting daughter 212 Bi. To avoid challenges with the short half-life of 212 Bi (60.6 min), a strategy has been to use 212 Pb as an in vivo generator for 212 Bi. In addition to the convenient longer halflife of 212 Pb, another advantage with the 212 Pb- 212 Bi in vivo generator is that it delivers about ten times the dose per administered activity unit compared to 212 Bi alone [3] , thus greatly reducing the amount of activity required. A 212 Pb-based radioimmunoconjugate is currently in clinical testing against peritoneal cancer [4] [5] [6] , after the preclinical efficacy [7] [8] [9] [10] and safety [11, 12] of the product have been thoroughly demonstrated.
The process for generating 212 Pb and the protocols for radiolabeling have evolved in line with the growing interest of 212 Pb as a therapeutic radionuclide. The first reported 212 Pb generator was based on a 228 Thsource [13] . The first generator had problems with radiolytic damage to the resin which caused decreased yields with time and was also associated with serious radiation safety issues. Generator systems based on emanation of 220 Rn [14, 15] improved radiation safety, but concerns with radiolytic damage were not completely overcome. A generator based on 224 Ra [16] has been designed to address challenges arising from use of 228 Th-based generators. This principle has become the most common way of generating 212 Pb. In the 224 Ra-based generator, 224 Ra is first separated from 228 Th using an anion exchange resin, followed by absorption of 224 Ra onto a macroporous, organic cationexchange resin column. Subsequently, 212 Pb can be eluted from the column using high acid concentrations.
In terms of 212 Pb-radiolabeling, the main improvement in protocol came with the emergence of the efficient lead-chelator TCMC (2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane) [17] . Many chelators have been assessed [18] , including the commonly used p-SCN-Bn-DOTA (2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid), but TCMC has become the chelation chemistry of choice as it creates a more stable complex at lower pH and provides more efficient conjugation than its DOTA analog [17] .
The 10.6 h half-life of 212 Pb imposes time constraints to its practical application and therefore rapid, efficient and reliable production and purification procedures are required. The previously mentioned 212 Pbradioimmunoconjugate undergoing clinical evaluation is based on the monoclonal antibody trastuzumab conjugated to TCMC. Baidoo and colleagues [19] have provided a detailed review of the protocol used for 212 Pb elution and radiolabeling of TCMC-conjugates that were generated for use in this trial. To summarize the protocol; A 212 Pbgenerator consisting of 224 Ra adsorbed on a column is shipped to the radiopharmacy at the hospital where 212 Pb is separated from 224 Ra when it is eluted in acid from the generator. The 212 Pb-eluate is then evaporated and digested three times with acid. The series of acid digestions are performed by dissolving 212 Pb in concentrated nitric acid (8 M) before evaporating the solution. The next step is reconstitution of 212 Pb in dilute nitric acid (0.1 M) before neutralization and radiolabeling. In Fig. 2A , a flow chart of the process is depicted. The authors reported that the preparation of an injectable dose required approximately 3.5 h, and after that some time will pass when quality control of the product is performed. Drawbacks with the protocol described above such as loss of 212 Pb due to time-consuming steps involving work and evaporation of strong acid solutions motivated us to investigate an alternative method of labeling monoclonal antibodies with 212 Pb which may be easier to perform in a hospital environment. Herein we have evaluated an in situ procedure of 212 Pb-labeling of TCMC-conjugated antibody in a solution of 224 Ra in equilibrium with daughter nuclides, which functions as a liquid 212 Pb generator, and subsequent removal of 224 Ra as an alternative strategy for preparing 212 Pbbased radioimmunoconjugates.
Methods

Radioactivity measurements
Radioactive samples were measured in the window 70-80 keV on a Cobra II Autogamma counter (Packard Instruments, Downer Grove, IL, USA) or from 60 to 110 keV and 520-640 keV on a Hidex Automatic Gamma Counter (Hidex, Turku, Finland). The energy ranges below 110 keV are assumed to mainly count X-rays and γ-radiation from 212 Pb with very little contribution from other radionuclides in the series. Since 224 Ra decay results in modest γ-emission in an energy region with more abundant γ from 212 Pb, the 224 Ra activity was determined indirectly from the counts in the 70-80 keV or 60-110 keV window. This was carried out by re-measuring the samples after minimum 3 days, when the initial 212 Pb present in the sample had decayed and equilibrium between 224 Ra and newly produced 212 Pb had been established. The 520-640 keV window was used to determine 212 Bi indirectly from the highly abundant 208 Tl γ. To quantify the amount of 212 Bi correctly, samples were measured after approximately 20 min, when transient equilibrium between 208 Tl and the 212 Bi parent had been established. In Table 1 all γ-rays in the 224 Ra-series with higher abundancy than 1%
are listed together with an overview of which nuclides in the series have X-and/or γ-rays that fall within the 60-110 and 520-640 keV windows respectively. A radioisotope calibrator (CRC-25R, Capintec Inc., Ramsey, NJ, USA) was used to measure amounts of radioactivity higher than 50 kBq. 224 Ragenerator setup have been described elsewhere [20] . In brief, 228 Th in 0.1 M HNO 3 was mixed with a portion of actinide resin and after a few hours a column was prepared by first applying a small amount of inactive actinide-resin before the portion containing 228 Th was loaded onto the column. The inactive resin was laid in the bottom to serve as a catcher layer in case of some release of 228 Th during operation of the generator. Radium-224 could be eluted regularly from the generator column with 1 M HCl. This crude eluate was loaded onto a second actinide resin cartridge for further purification. The second cartridge was washed with 1 M HCl to produce an eluate containing 224 Ra. This solution was evaporated to dryness and the residue was dissolved in 0.2 mL or more of 0.1 M HCl. All work described in this paragraph was performed in a glove-box with negative pressure. At its maximum capacity, the 224 Ra-generator column contained approximately 2 MBq of 228 Th. The 224 Ra-generator column was stored inside the glove-box in a 2.5 cm thick lead pot which reduced the dose rate at 30 cm distance from the source to approximately 1.3 μSv/h. The handling of the generator and the produced eluates was also performed behind similar shielding using lead-bricks.
Radiolabeling of antibodies
The humanized anti-HER2 IgG1 monoclonal antibody trastuzumab (Herceptin, Roche, Basel, Switzerland) conjugated to a chelator, TCMC (Macrocyclics Inc., Dallas, TX, USA), was used for radiolabeling with 212 Pb.
Before conjugation to TCMC, the original buffer of trastuzumab was exchanged with carbonate buffer (0.1 M NaHCO 3 and 5 mM Na 2 CO 3 in metal free water of pH. Eur grade). To achieve this, a solution of trastuzumab was washed four times with carbonate buffer using a centrifugal concentrator (Vivaspin 15R, 30 or 50 kDa MWCO, Sartorius Stedim Biotech, Göttingen, Germany). During each wash trastuzumab was concentrated by a factor of ten. The concentration of antibody in the new buffer was determined by UV-spectrophotometry (Hitachi U-1900, Hitachi High-Technologies Corporation, Tokyo, Japan) using the standard absorbance value of 1.4 for immunoglobulins at 280 nm for 0.1% solutions. A solution of TCMC dissolved in 5 mM HCl was added to trastuzumab in carbonate buffer in a five-to tenfold molar excess of chelator to antibody. The mixture reacted for 2 h at room temperature with gentle agitation. To remove unconjugated chelator from TCMC-trastuzumab and reduce pH, the carbonate buffer was exchanged with 0.9% NaCl, using a centrifuge filtering cartridge (Vivaspin 15R, 30 or 50 kDa MWCO). The sample was diluted 1:10 with 0.9% NaCl and the TCMC-antibody conjugate was concentrated tenfold by centrifugation. This procedure was repeated a total of three times. The described protocol for TCMC-conjugation has previously shown to yield a chelator to antibody ratio of 2-5 [10, 17] . The TCMC-trastuzumab conjugate was stored at 4°C until radiolabeling.
A solution of 224 Ra in equilibrium with progeny in 0.1 M HCl and 0.5 M NH 4 OAc was used for radiolabeling. The pH of the solution was verified to be approximately 5-6 using pH paper (Merck Millipore general pH indicator paper, Merck KGaA, Darmstadt, Germany). TCMCtrastuzumab and the 224 Ra-solution were mixed and incubated usually for minimum 30 min on a ThermoMixerR (Eppendorf AG, Hamburg, Germany) at 37°C and 750 rpm. This solution, consisting of 212 Pblabeled trastuzumab and free 224 Ra and daughters is referred to as the "reaction mixture". Different concentrations of TCMC-trastuzumab conjugate (in the range from 0.1 to 6 mg/mL) were radiolabeled using the described method. Typically, the reaction mixture volume was between 30 and 130 μL. In one experiment, the influence of incubation time on yields of 212 Pb and 212 Bi labeling of TCMC-trastuzumab (4 mg/mL) was evaluated by taking out samples from the reaction vial after 5, 15 and 30 min. The radiochemical purity (RCP) of the samples was analyzed by instant thin layer chromatography (ITLC). Experiments to examine possible radiolysis of the antibody during labeling was also performed. The reaction mixture was stored overnight to obtain elevated self-dose to the radiolabeled product followed by analysis with high-performance liquid chromatography (HPLC) or measurement of the immunoreactive fraction.
Instant thin layer chromatography assay procedure
The RCP of the 212 Pb labeled antibody in the reaction mixture was evaluated using ITLC strips (model # 150-772, Biodex Medical Systems Inc., Shirley, NY, USA). An aliquot of reaction mixture was mixed with a twofold excess (by volume) of formulation buffer consisting of 7.5% human serum albumin, 5 mM EDTA in Dulbecco's PBS, and adjusted to pH 7 with NaOH. The reaction mixture with added formulation buffer was whirl-mixed for 4-5 s and left for another 5-10 min to allow chelation of unbound radioisotopes with EDTA. An ITLC strip was spotted with 1-5 μL of sample at the origin line and placed in a small beaker with about 0.5 mL of 0.9% NaCl for development. After the solvent front had moved to the designated solvent front line, the strip was cut in half at the cut line and each half was placed in a glass tube for counting. In this system 212 Pb-TCMC-trastuzumab does not migrate Table 1 Overview of which nuclides in the 224 Ra-series having X-and/or γ-lines in the 60-110 keV and/or 520-640 keV energy range. Gamma lines which are outside these energy ranges are shown in the "Other" column. The abundancy of the lines is given in parentheses and all radiation with 1% or higher abundancy is shown. from the bottom half (B) whereas 212 Pb (and other free radionuclides) complexed with EDTA migrates to the upper half (U). The percent radionuclide bound to the antibody was determined as:
where CPM denotes the counts per minute.
Measurement of immunoreactive fraction
The immunoreactive fraction of 212 Pb-TCMC-trastuzumab was determined in a one-point, live-cell binding assay, performed according to a previously published procedure [21] . Briefly, samples of 16-20 × 10 6 HER2 expressing human osteosarcoma cells, OHS [21, 22] , were prepared and incubated at room temperature with 212 Pb-TCMCtrastuzumab or blocked with an excess of trastuzumab prior to addition of 212 Pb-TCMC-trastuzumab. The percent bound activity after washing was determined for each sample, and the immunoreactive fraction of 212 Pb-TCMC-trastuzumab was estimated to be the total bound minus the unspecific bound in the blocked samples.
High-performance liquid chromatography
HPLC was performed in a 1260 Infinity VL System (Agilent Technologies, Santa Clara, CA, USA) using a size exclusion TSKgel G3000SWxl column (Tosoh Bioscience, Griesheim, Germany, product number 08541) with UV (220 and 280 nm) and radiometric (Radiomatic 150TR Flow Scintillator Analyzer, Perkin Elmer, Waltham, MA, USA) detection. The mobile phase was 50 mM sodium phosphate (pH 7.0) containing 250 mM NaCl with a flow rate of 0.8 ml/min.
Purification of radiolabeled antibodies
Two different methods of purification were evaluated in this study: purification using a centrifugal concentrator and purification with a desalting column. In the first case the reaction mixture was loaded in a concentrator spin tube (Vivaspin 4, 50 kDa MWCO, Sartorius Stedim Biotech, Göttingen, Germany) and diluted with 0.9% NaCl until the total volume was 4 mL. The content was concentrated tenfold by centrifugation. The concentrate (C) was collected and measured immediately (t = 0). The yield (Y) of the purification process was estimated as the percentage of antibody-bound 212 Pb-activity in the concentrate:
The total activity (T) loaded onto the spin concentrator tube was determined from a sealed reference sample prepared from an aliquot of the reaction mixture taken prior to purification. A minimum of 3 days after the first measurement (t = eq), when equilibrium between 224 Ra and 212 Pb was reached, all samples were measured again and the percentage of 224 Ra remaining in the concentrate was calculated:
The second purification method utilized a Sephadex G-25 PD-10 column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) for separation of the radiolabeled TCMC-trastuzumab from unbound radionuclides. The column was equilibrated with approximately 25 mL of Dulbecco's PBS supplemented with 0.5% bovine serum albumin as elution buffer. Both the crude reaction mixture and reaction mixture added a tenfold excess (by volume) of formulation buffer was purified with PD-10. In the latter case the reaction mixture was reacted with formulation buffer for at least 10 min to allow chelation of unbound radioisotopes with EDTA before application. Quenching of the reaction mixture with EDTA prior to application on the PD-10 column was performed to investigate whether this could lead to more efficient separation of the radiolabeled antibody from unconjugated nuclides. The sample was loaded on top of the column and allowed to enter the column bed completely before elution buffer was added. The elution process was continued until seven fractions of 1 mL each was collected in Eppendorf tubes, before the activity in all fractions were measured immediately. The radiolabeled antibody was typically eluted in fractions 3-5 (F3-F5), and the yield of the process was estimated to be the percentage of antibody-bound 212 Pb-activity in these fractions:
The total activity (T) loaded onto the PD-10 column was determined from a sealed reference sample prepared from an aliquot of the reaction mixture taken prior to purification. RCP of the product in fraction 4 was determined by the previously described ITLC procedure. After at least 3 days, the samples were re-measured and the percentage of 224 Ra remaining in fraction 3-5 was calculated:
To assess co-elution of radionuclides with the protein fractions an experiment was performed where the radiolabeling and PD-10 purification were performed as described above, but unconjugated trastuzumab was used instead of TCMC-conjugated trastuzumab. The presence of 212 Pb and 212 Bi in the seven collected fractions was determined by measurement in the 60-110 and 520-640 keV windows. By measuring the samples 5 min, 20 min, 1 h, 1 day and 5 days after the PD-10 purification was finalized, the decay rate could also be assessed. This was necessary to ascertain if the γ-activity in the 520-640 keV window was reflecting the presence of 212 Bi in addition to 208 Tl. From the day 5 measurements, when all samples had reached equilibrium, the amount of 224 Ra was determined. 212 Pb daughter 212 Bi by the TCMC-chelator In a 224 Ra-solution in equilibrium the ratio of 212 Bi activity to 212 Pb activity is approximately equal to one. A sealed 224 Ra sample in equilibrium with progeny was used as a reference to determine an efficiency factor (Bq/CPM) for the 60-110 and 520-640 keV windows. After PD-10 purification of reaction mixture quenched with EDTA, fraction 4 was measured 10 min, 20 min, 60 min and 22 h after end of purification. The 212 Bi to 212 Pb ratio at the different time points was estimated using the efficiency factors. An online universal decay calculator (http://www. wise-uranium.org/rcc.html) was used to determine the theoretical 212 Bi to 212 Pb ratios as a function of time based on different initial 212 Bi to 212 Pb ratios, ranging from a sample of pure 212 Pb without any 212 Bi present to a sample where the activity ratio is equal to one. Under the assumption that all activity in fraction 4 straight after purification was bound to the antibody-conjugate, an estimate of the portion of 212 Bi retained in the TCMC-chelator could be deduced by comparing the experimentally determined ratios with plots of ingrowth for different theoretical 212 Bi to 212 Pb ratios.
Retention of the α-emitting
Results and discussion
Radiolabeling of TCMC-trastuzumab
Radiolabeling of TCMC-trastuzumab with 212 Pb in a solution of 224 Ra in equilibrium with daughter nuclides was successful. The procedure yielded a product with RCP above 90% already at 0.15 mg/mL of antibody conjugate, and above 95% from 1 mg/mL and at higher concentrations (Table 2 ). In three of the labeling experiments, the immunoreactive fraction of the product was determined. It ranged from 57% to 66%, which is in line with previously published results on the immunoreactivity of 212 Pb-TCMC-trastuzumab [10, 23] labeled with the method described by Baidoo et al. [19] .
Because the labeling was performed in a solution of 224 Ra in equilibrium with daughters, 212 Bi will be present during the incubation period. The RCP was therefore also measured in the 208 Tl window after transient equilibrium was reached to account for 212 Bi. This resulted in values ranging from 56% to 86%, indicating that 212 Bi also conjugates directly to TCMC under these labeling conditions. It was found that 212 Pb was complexed almost quantitatively already after 5 min reaction time at a TCMC-trastuzumab concentration of 4 mg/mL (Table 3) . At the same time, more than 70% of the 212 Bi was complexed, and it increased up to 86% after 30 min. Altogether, these results demonstrate that TCMC-trastuzumab is labeled with 212 Bi in addition to 212 Pb, albeit the reaction kinetics with 212 Bi is slower. The successful 212 Pb-labeling over a range of antibody concentrations demonstrates that a variety of specific activities of the radioimmunoconjugate can be achieved. Since this study mainly was intended to show proof of concept, relatively low activity levels were used compared to what is expected in a clinical setting. The radiolabeling was therefore performed in quite small volumes, typically from 30 to 130 μL, to simulate relevant clinical activity concentrations. Due to the low volumes, it was possible to achieve relatively high specific activities of the end product, despite the low activity used. The highest specific activity of 212 Pb-TCMC-trastuzumab achieved in this study was approximately 30 MBq/mg which is comparable to what was used in a recent clinical study with 212 Pb-TCMC-trastuzumab [4] . Upon complete decay of 224 Ra, stable 208 Pb is formed, which can compete with 212 Pb on complexation with the TCMC chelator. With the activity levels used here, there was no indication that the presence of 208 Pb influenced the yield of the radiolabeling due to the relatively high specific activity it was possible to achieve. However, the situation might differ when higher 224 Ra activity is used and the following estimation was made: Assume 1 mg antibody labeled in a solution of 100 MBq 224 Ra. This corresponds to 4 Ra will form approximately 4.5 × 10 13 208 Pb atoms. These numbers indicate that the presence of 208 Pb should not influence the yield of radiolabeling to a significant extent, not even for a product with high specific activity. 212 Pb-TCMC-trastuzumab from 224 
Separation of
Ra
The desired end-product of the process described in this study is a solution of pure 212 Pb-labeled TCMC-antibody. To achieve the desired end-product, the solution with 212 Pb-labeled antibody conjugate was purified to remove free 224 Ra and other unconjugated daughter nuclides. Two different purification methods were evaluated; purification by centrifugal concentration and purification with a desalting column.
Both methods are based on a size-dependent separation of the antibody-conjugate from low molecular weight compounds such as free ions, unbound chelator molecules and salts. Use of the centrifugal concentrator for separation of 212 Pb-TCMCtrastuzumab from cationic 224 Ra and other unconjugated daughter nuclides yielded 70.5 ± 9.6% (n = 6) of the antibody-bound 212 Pb activity in the concentrate. The loss of approximately one third of 212 Pb-labeled trastuzumab due to the procedure is significant, but still in line with reported yields (73 ± 3%) of 212 Pb-TCMC-trastuzumab after PD-10 column purification [19] . The amount of 224 Ra remaining in the concentrate was 25.9 ± 13.1% (n = 6), i.e., the separation of 224 Ra from the radioimmunoconjugate was only 75% complete. The ratio of 212 Pb-TCMC-trastuzumab to 224 Ra improved from 1:1 to only about Pb mixtures is feasible. To examine whether any of the radionuclides in the 224 Ra-solution bind non-specifically to trastuzumab and thereby co-elute with the protein fractions, an experiment was performed where the radiolabeling protocol and PD-10 purification were performed as usual, except that TCMC-trastuzumab was replaced with trastuzumab. The presence of 212 Bi, 212 Pb and 224 Ra was assessed by measuring the seven collected fractions at different time points after the PD-10 purification was Table 2 Radiochemical yield after labeling of TCMC-trastuzumab conjugate with 212 Pb in a solution containing 224 Ra in equilibrium with daughter nuclides. The radiochemical purity (RCP) for 212 Pb was determined using instant thin layer chromatography strips. 224 Ra in equilibrium with daughter nuclides. The radiochemical purity (RCP) for 212 Pb and 212 Bi, respectively, was determined using instant thin layer chromatography strips.
Incubation time (min)
RCP (%) 212 Pb 212 finalized. The results are presented in Fig. 3 as a percentage of total activities in the 60-110 and 520-640 keV windows respectively. Fig. 3A shows a significant amount (28%) of 212 Bi co-eluting with the antibody in fractions 4 and 5 when no EDTA was present. It is seen from the decay rate that the activity measured in this window (520-640 keV) clearly originates from ingrowth of 208 Tl from 212 Bi as it decays with the halflife of the mother 212 Bi. When EDTA was used to quench the reaction mixture (Fig. 3B) , the co-elution of 212 Bi was reduced to 1.3% in the same fractions. Co-elution of 212 Pb was insignificant in fraction 3 and 4 of the PD-10 eluate when EDTA was present (Fig. 3D) , and below 2% in fraction 5. Fig. 3C shows that without EDTA present, approximately 5% of the total 212 Pb activity co-eluted with the antibody in fractions 3-5. As can be seen from the measurements on day 5, co-elution of 224 Ra was negligible (less than 0.7%) in both cases. Altogether, the results clearly show that using EDTA to quench the reaction mixture prior to purification on the PD-10 column maximizes the product purity when a 224 Ra-solution is used for preparing 212 Pb-based radioimmunoconjugates. This measure removes non-specific bound 212 Bi and 212 Pb from the antibody fractions, and at the same time gives less remaining 224 Ra in the end product. 212 Bi by the TCMC-chelator upon 212 
Retention of
Pb decay
It is of interest to have knowledge about the fate of 212 Bi formed when 212 Pb chelated to TCMC decays. To avoid radiotoxicity caused by free 212 Bi it is desirable that a substantial fraction of 212 Bi is retained by the TCMC-chelator upon decay. Mirzadeh and colleagues found that 36% of 212 Bi was released from the DOTA-chelator when 212 Pb decayed and they claimed the breakup of the complex was due to internal conversion from γ-rays emitted from excited 212 Bi nuclei [26] . We have found no corresponding examination for the retention of 212 Bi by the TCMC-chelator when 212 Pb decays, and therefore made an estimation based on our data. A sample of radiolabeled TCMC-trastuzumab was mixed with EDTA solution and stored until less than 5% of the 212 Bi originally complexed to TCMC had decayed. We thereafter determined the 212 Bi to 212 Pb ratio in fraction 4 of the PD-10 purified product Table 4 Purification of 212 Pb-labeled TCMC-trastuzumab from 224 Ra and other unconjugated daughter nuclides using Sephadex G-25 PD 10 gel filtration desalting single-use columns.
No EDTA (n = 6) EDTA (n = 7)
Yield of 212 224 Ra remaining in purified fractions Fraction 3 0.6 ± 1.2% 0.1 ± 0.1% Fraction 4
2.1 ± 2.6% 0.8 ± 0.7% Fraction 5 0.5 ± 0.6% 1.3 ± 0.7% Total 3.2 ± 4.2% 2.2 ± 1.1% Fig. 3 . The measured activity in the energy ranges 520-640 keV (A and B) and 60-110 keV (C and D) in each of the seven collected fractions after PD-10 purification of trastuzumab (not TCMC-conjugated) radiolabeled with 212 Pb using a 224 Ra solution. The bar graphs illustrate the presence of 212 Bi by an indirect assessment from the 208 Tl γ in the 520-640 keV window with (B) and without (A) use of EDTA to quench the reaction mixture prior to loading it on the PD-10 column. Similarly, the presence of 212 Pb is assessed from the measurements in the 60-110 keV window with (D) and without (C) EDTA present. The activity is displayed as the decay corrected percentage of the total activity loaded on the column at different time points after finalizing the PD-10 purification. Each bar represent data from two parallel samples.
at different time points after finalizing the purification. These ratios are plotted in Fig. 4 together with theoretical 212 Bi to 212 Pb ratios as a function of time for a few selected, initial 212 Bi to 212 Pb relationships. Depending on the initial amount of 212 Bi present, the 212 Bi/ 212 Pb ratio increases to varying degrees before it reaches a maximum plateau where the nuclides are in transient equilibrium. Under the assumption that all activity in fraction 4 is bound to the antibody-conjugate straight after purification and by taking into account ingrowth of 212 Bi from 212 Pb during the time from finalizing the purification to the time of measurement, it was estimated that no less than about 60% of the 212 Bi was associated with the TCMC-chelator after 212 Pb decay. This is seen in Fig. 4 , where the red filled circles representing the experimental data follows the shape of the curve that corresponds to a 212 Bi to 212 Pb ratio of 0.6 at time zero. We also determined the retention of 212 Bi by the TCMC chelator after 212 Pb decay with a different method. A sample of radiolabeled TCMC-trastuzumab was stored in an EDTA solution overnight, and the RCP was analyzed. The 212 Bi to 212 Pb ratio in the lower half of the ITLC strip was determined and all the activity measured here was assumed to be complexed to TCMC-trastuzumab. This ratio was compared with the 212 Bi to 212 Pb ratio in a reference sample of 224 Ra in equilibrium in daughters. With this method it was found that approximately 70% of the 212 Bi remained associated with the TCMC-chelator after 212 Pb decay. The values we found are in good agreement with each other and the previously mentioned data on 212 Bi retention by the DOTA-chelator [26] . It has been claimed that the four N-donor and four O-donor atoms of the TCMC-chelator will provide for good binding abilities with bismuth [27] , and thus the relatively high retention of 212 Bi in the TCMC-chelator is not unlikely.
Evaluation of possible radiolytic problems at elevated radiation doses
As mentioned previously in the discussion, the current study was carried out with relatively low activity levels and radiolytic problems may arise when higher, clinical relevant activity of 224 Ra-solution is used. A potential drawback of using 224 Ra in equilibrium with 212 Pb instead of pure 212 Pb in the radiolabeling reaction, is the elevated radiation dose to the reaction solution due to increased α-particle activity. The radiation exposure to the antibody-conjugate is likely to be at its highest during the radiolabeling procedure. At that time 224 Ra and all progeny will contribute to the dose, whereas after purification it will mainly be dose delivered from 212 Pb and daughters. The total decay energy (excluding photons) from 224 Ra and progeny is 27.8 MeV, compared to only 8.8 MeV released from decay of 212 Pb and daughters. To expose the antibody to a high radiation dose, after the incubation period of 30 min, we continued to store the 212 Pb-labeled TCMC-trastuzumab in the 224 Ra-solution in equilibrium until a dose of approximately 700 Gy was achieved. Analysis with size-exclusion HPLC showed a peak including 96% of the total radioactivity at a time consistent with intact TCMC-trastuzumab, with less than 1.3 and 2.9% associated with higher and lower molecular weight compounds respectively. The 212 Pb-TCMC-trastuzumab exposed to 700 Gy was also compared with unlabeled TCMC-trastuzumab with detection of absorption at 280 nm. The results showed a peak of molecular weight compounds lower than the IgG when the radiolabeled antibody was analyzed. This peak comprised approximately 11% and was not seen with the unlabeled TCMC-trastuzumab and is therefore likely caused by radiolytic degradation of the protein. The amount of high molecular species was similar between the two samples (less than 1.6%). However, the apparent radiolytic damage to a fraction of the antibodies did not seem to significantly influence the immunoreactive fraction of the product. Two samples of 212 Pb-labeled TCMC-trastuzumab exposed to 100 and 700 Gy, was purified with a PD-10 column and the immunoreactivity of fraction 4 was determined to be 60 and 57% respectively, with low (less than 3%) non-specific binding in both cases. This is in accordance with results from the literature, were exposure of up to 1000 Gy was tolerated without significantly reducing the cell binding fraction of a radiolabeled antibody [29] . Altogether, the examination of possible radiolytic effects at higher radiation doses indicate that the radiation dose to the antibody should be kept significantly below 700 Gy. In the phase I study of intraperitoneally administered 212 Pb-TCMC-trastuzumab the highest dose the patients received was 27.4 MBq/m 2 [5] . By using an average body surface area of 1.79 m 2 found in a study of adult cancer patients [28] this dose corresponds to 49 MBq per patient. To prepare a patient dose with this activity it is reasonable to assume that an activity of 100 MBq 224 Ra should be sufficient as it corresponds to about the double of the highest dose of 212 Pb-TCMC-trastuzumab administered to patients in the phase I trial. The radiation dose to the antibody solution during a 30 min labeling with 100 MBq of 224 Ra in a reaction volume of 1.5 mL, which is compatible with the PD-10 gel exclusion purification format, was estimated to be 534 Gy. If a further decrease in dose should be necessary, it is possible to reduce the labeling time as we have shown that the reaction between 212 Pb and TCMC is very fast and similar yields could be achieved after 5 and 30 min when 4 mg/mL TCMCtrastuzumab was used. Based on the calculations, it is predicted that the method described herein could be useful also in a clinical setting where high activity levels are used.
Discussion of the feasibility of the proposed method
The current study demonstrates that a TCMC-conjugated monoclonal antibody can be efficiently labeled with 212 Pb from solutions of 224 Ra in equilibrium with progeny. When a concentration of 4 mg/mL of TCMC-trastuzumab was used, the labeling with 212 Pb was close to quantitative after only 5 min (Table 3) . At this concentration it was also observed that the major part of the 212 Bi would be chelated by the antibody conjugate. Subsequently, the radiolabeled conjugate can be separated from the generator nuclide 224 Ra using desalting gel exclusion separation. Fig. 2 shows a flow chart of our proposed process compared to the method presented by Baidoo et al. [19] . In contrast to the current ion exchange based generators, which may be eluted several times, the liquid 212 Pb generator described here is designed for preparation of a single dose only. With our proposed method, a ready to use 224 Ra solution can be shipped from a centralized supplier to the end user. This is beneficial both from a logistic point of view and because Fig. 4 . The relationship between the 212 Bi and 212 Pb activity in a sample plotted as a function of time and compared with the experimentally determined ratios in fraction 4 of the PD-10 purified product (filled red circles). The solid and dotted lines represent ratios determined theoretically from a few selected, initial 212 Bi/ 212 Pb-ratios, ranging from a sample of pure 212 Pb without any 212 Bi present (solid blue line in the bottom) to a sample where the activity ratio is equal to one (solid black line on top). Ingrowth of 212 Bi from 212 Pb were calculated using a universal decay calculator (http://www.wiseuranium.org/rcc.html). The filled red circles represent data from 4, 2, 3 and 3 parallel experiments for the 10, 20, 60 min and 22 h time points respectively. the work required by the end user is reduced and simplified. We believe it is an advantage with our method that the steps involving handling and evaporation of concentrated acid solutions with high radioactivity levels can be completely avoided in the hospital or radiopharmacy setting. An additional benefit with eliminating the acid digestion procedures is that the total preparation time at the hospital will be shorter, since it is only the actual antibody labeling and purification that needs to be performed. Baidoo et al. reported that this part of the process required only 80 min of the total preparation time of an injectable dose of about 210 min [19] . A shorter preparation time reduces the activity loss caused by decay and will therefore lead to a higher amount of 212 Pb administered to the patients. This is beneficial both to limit the amount of free daughter nuclides in the product at time of injection and to minimize the risk of possible problems with radiolysis of the antibody.
On evaluation of our proposed method for radiolabeling of antibodies, it is also important to address the radiation safety requirements. As with all procedures involving open sources of α-emitting radionuclides, precautions must be followed to avoid inhalation or ingestion. All handling should therefore be performed in either a biosafety bench or in a glove-box under negative pressure to protect the worker. This is especially important when handling the 224 
